Pentoxifylline

Peripheral vascular disease, a chronic circulatory disorder with high incidence among middle-aged and elderly people, often causes intermittent claudication, rest pain, and even ischemic tissue necrosis. There has been a long-term clinical lack of safe medications that can both improve microcirculation and regulate blood flow. Pentoxifylline is a methylxanthine derivative that increases intracellular cyclic adenosine monophosphate levels through non-selective inhibition of phosphodiesterase. It can not only reduce blood viscosity and improve erythrocyte deformability, but also inhibit platelet aggregation and dilate peripheral and cerebrovascular microcirculation. In addition to intermittent claudication caused by chronic peripheral arterial disease, this drug can also be used for microcirculation disorder-related diseases such as sequelae of ischemic stroke and diabetic retinopathy, with its applicable population covering middle-aged and elderly patients with chronic vascular diseases and people with diabetes combined with vascular complications.

The global pentoxifylline market size was approximately USD 420 million in 2023, and is expected to grow steadily at a compound annual growth rate of 3.1% from 2024 to 2030. The growth drivers mainly come from the rising prevalence of peripheral vascular diseases and the increased diagnosis and treatment rate of diabetes-related microvascular complications. The domestic market is currently dominated by generic drug supplies. In 2022, the sales of pentoxifylline in domestic sample hospitals exceeded RMB 230 million, among which the injection formulation accounted for more than 75%. At present, more than 20 enterprises have obtained the production approvals for preparations, and the API suppliers are mainly domestic local enterprises. The overall market is highly competitive, with no exclusive monopoly pattern.

The original developer of pentoxifylline is Sanofi, with the original brand name Trental. Its core compound patent expired worldwide in 1989. The main formulations approved for the original drug include enteric-coated tablets (400mg) and injections (100mg/5ml, 300mg/15ml). Among them, the original 400mg enteric-coated tablets have been included in the Reference Preparation Catalogue of China NMPA, and the injection is also listed in the FDA Reference Preparation Catalogue. At present, the pentoxifylline APIs of more than 15 domestic enterprises have obtained A status through CDE registration, which can be legally supplied to preparation manufacturers. Meanwhile, generic drugs of multiple formulations such as enteric-coated tablets, injections and sustained-release tablets have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of pentoxifylline impurity reference standards. Most of the products are available from stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can fully meet the relevant experimental needs of API R&D, quality research and generic drug consistency evaluation.